Topics:

Hematologic Malignancies

Hematologic Malignancies

Hodgkin lymphoma survivors who were treated with infradiaphragmatic radiotherapy have an increased risk of developing diabetes mellitus, says a new study.

A study of more than 4,500 patients with acute myeloid leukemia (AML) found that predicting resistance to therapy remains an elusive practice.

Multiple myeloma patients may already suffer from sensory deficits prior to treatment, likely due to disease-related decreases in peripheral innervation density.

The rationale for maintenance therapy in indolent non-Hodgkin lymphoma was derived from historical data suggesting that despite robust response rates to standard therapy, most patients eventually relapse and disease-free intervals become progressively shorter.

While definitions of follicular lymphoma maintenance therapy in clinical trials and clinical practice have been somewhat variable, ideally maintenance therapy would be limited to patients in complete remission or with minimal residual disease following initial therapy

The optimal treatment strategy for newly diagnosed multiple myeloma is consolidation with melphalan, stem-cell transplantation, then lenalidomide maintenance.

Continuous treatment with lenalidomide plus dexamethasone improved progression-free and overall survival in transplant-ineligible multiple myeloma patients.

Pages

Subscribe to Hematologic Malignancies on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.